Latigo Biotherapeutics, Inc. Common Stock (LTGO) stock: key figures, P/E, revenue and dividend
Health Care · United States
Latigo Biotherapeutics, Inc. Common Stock financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 USD | 0.00 USD |
| Operating income | -63.45 m USD | -110.39 m USD |
| EBIT | -63.45 m USD | -110.39 m USD |
| Net income | -61.18 m USD | -109.17 m USD |
| Diluted EPS – continuing operations | -1.02 USD | -1.81 USD |
Full history since 2024, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
More stocks
- Shenzhen LeoKing Environmental Group Co. Ltd. A (301305.SZ)
- FastPartner AB (FPAR A.ST)
- Criteo S.A. (CRTO)
- WAM Capital Ltd (WAM.AX)
- Shenzhen Bingchuan Network Co Ltd (300533.SZ)
- Cosonic Intelligent Tech Co Ltd (300793.SZ)
- Paul Hartmann (PHH2.F)
- Jintuo Technology Co Ltd (603211.SS)
- Standard Foods Corp (1227.TW)
- Nextdoor Holdings, Inc. (NXDR)
- Lectra SA (LSS.PA)
- Zhuhai Enpower Electric Co Ltd (300681.SZ)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.